ArticleJournal of cardiothoracic surgery2025
Hybrid prosthesis in frozen elephant trunk procedures for hereditary thoracic aortic diseases: a 14-year single-aortic center experience.
Article in Journal of cardiothoracic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is a lack of data regarding the use of hybrid stent graft prostheses in patients with hereditary thoracic aortic disease (HTAD) involving the aortic arch and proximal descending aorta. This retrospective analysis aimed to evaluate the short- and mid-term outcomes of hybrid stent-graft prostheses in Frozen Elephant Trunk (FET) procedures for patients with HTAD, with a particular focus on its safety and feasibility.
methodsA total 280 patients who underwent FET procedures between October 2010 and November 2024 were retrospectively analysed in compliance with the 2024 EACTS/ STS recommendations for shared decision-making within the multidisciplinary aortic team. Among them, 51 patients had genetically confirmed HTAD (Marfan syndrome (FBN1), Loeys-Dietz syndrome (TGFBR1, TGFBR2, SMAD3, TGFB2), vascular Ehlers-Danlos syndrome (COLSA1), and non-syndromic HTAD (ACTA2, MYH11, MYLK)). The Thoraflex™ prosthesis was implanted in 50 of the 51 patients. Short- and mid-term outcomes were assessed descriptively. Survival and subsequent thoracic aortic intervention rates were analysed using the Kaplan-Meier method.
resultsThe overall 30-day mortality was 2.0% (n = 1). Perioperatively, permanent neurological deficit was 3.9% (n = 2), with minor disability on the modified Rankin Scale (mRS 1 and 2). There were no instances of paraplegia. The median follow-up was 4.0 years. The 1-, 3- and 5-year overall survival rate was 93.9%, 90.6%, and 90.6%, respectively. Freedom from subsequent aortic interventions was at 1, 3, 5 years 55.8%, 45.6%, and 33.1%. Early device-related complications occurred in 7 patients (13.7%), including intraluminal FET thrombosis in 4 patients (12.5%) and distal stent graft-induced new entry in 3 patients (9.4%). Mid-term device-related complications occurred 2 patients (4.3%).
conclusionsHybrid stent graft prostheses can be safely implanted with the FET technique in elective and acute HTAD patients with arch and proximal descending aortic disease. Our single-center short- and mid-term outcomes are encouraging, but long-term durability and efficacy are not yet established. This warrants multi-center studies with extended follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.